Lipoprotein (a) Molarity Assay
Lipoprotein, Low-Density, Antigen, Antiserum, Control. 510(k) K253069, from Diazyme Laboratories, Inc. (Poway, CA). Product code DFC, class 2.
As of Nov 19, 2026, K253069 is an FDA 510(k) held by Diazyme Laboratories, Inc., substantially equivalent on Jun 16, 2026 after 266 days, with no recalls tied to it in FDA's recall database.
- Review time: 266 days
- Recalls: 0
The Lipoprotein (a) Molarity Assay is intended as an in vitro test for quantitative determination of Lipoprotein(a) [Lp(a)] concentrations in human serum and plasma on validated automated analyzers. The measurement of Lp(a) is useful in evaluating lipid metabolism disorders and assessing atherosclerotic cardiovascular disease risk, when used in conjunction with clinical evaluation and other…
- Diazyme Lipoprotein (a) AssayK180074 · Diazyme Laboratories, Inc. · Mar 22, 2018
- Tina-quant Lipoprotein(a) Gen.2 MolarityK241220 · Roche Diagnostics Operations · Jan 24, 2025
- Lp(a) UltraK211058 · SENTINEL CH. SpA · Dec 22, 2022
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Sep 23, 2025
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5600
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files